Company: SRPT
Filing Date: 2025-08-13
Form Type: 8-K
Source: 0001193125-25-179819
Chunk: 0

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

In connection with the strategic restructuring and pipeline prioritization of Sarepta Therapeutics, Inc. (the “ Company”), Bilal Arif’s employment will end effective September 16, 2025. Mr. Arif served as the Executive Vice President, Chief Technical Operations Officer of the Company until August 12, 2025 and will serve as Special Advisor to the President for the remainder of his employment. The Company thanks Mr. Arif for his substantial contributions during a transformational period for the Company and wishes him well.

The Company entered into a Separation and Consulting Agreement and General Release (the “ Agreement”) with Mr. Arif dated August 12, 2025, pursuant to which he will remain a consultant to the Company following his termination of employment through December 31, 2025. Pursuant to the terms of the applicable equity award agreements, the outstanding equity awards issued to Mr. Arif as of August 12, 2025 will continue to vest through the period in which Mr. Arif continues to be employed by or provide consulting services to the Company. Under the Agreement, the Company has agreed to pay Mr. Arif severance in the lump sum amount of $576,700 as well as a consulting fee of $400 per hour for the consulting services provided.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form10-Qfor the quarter ended September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                      Sarepta Therapeutics, Inc.  
  Date: August 13, 2025      By:      /s/ Douglas S. Ingram       
                                      Douglas S. Ingram